EGFR and ovarian cancer: A phase II trial (NCT01447706) evaluating paclitaxel +/- seribantumab in platinum-resistant ovarian cancer demonstrated improved PFS in tumors positive for HRG, betacellulin (an EGFR ligand), HER2, HER3, or EGFR.[121] A phase II trial of erlotinib +/- seribantumab in patients with platinum-resistant, TKI-naïve, wild-type EGFR NSCLC showed no PFS or OS benefit.[122] The phase II SHERLOC trial of chemotherapy (docetaxel or pemetrexed) +/- seribantumab in heregulin positive NSCLC is ongoing (NCT02387216).